clinical trial · NCT06982963
Randomized, Double Blind, Placebo-controlled Phase 2 Study in Adults With Celiac Disease
Celiac DiseaseFB102Placebo
brief summary
This study is a randomized, double-blind, placebo controlled clinical study to assess the efficacy, safety, pharmacokinetics (PK) and pharmacodynamics (PD) of FB102 in adult participants with well controlled (on a strict GFD) CeD following an oral gluten challenge.
started
Aug 4, 2025
primary completion
Feb 28, 2027
completion
Feb 28, 2027
last updated
Nov 18, 2025
official title
A Multicenter, Randomized, Double-blind, Placebo-controlled Phase 2 Study to Evaluate the Efficacy and Safety of FB102 in Adult Participants With Celiac Disease on a Gluten Free Diet
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol